Silo Pharma closed at $1.33 on Nov 4, up 3.91%, 98.3% below its 52-week closing high. Volume of 18.4K shares was 0.76× its 20-day average (below normal).
Split-adjusted performance: -8.3% over one month, -78.9% over six months, -82.9% over one year.
Short interest was 22.1K shares at the Oct 15 settlement, down 36.7% from the prior report (2.1% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SILOSilo Pharma | $1.33 | +3.91% | −78.9% | −100.0% | — | — | $2.9M | |
| GRIGRI Bio | $1.43 | −7.14% | −39.4% | — | — | — | $3.1M | Compare |
| MBIOMustang Bio | $0.4138 | +1.07% | −44.6% | — | — | — | $3.1M | Compare |
| JUNSJupiter Neurosciences | $2.46 | +1.23% | −91.0% | — | −9380.9% | — | $3.2M | Compare |
| SXTP60 Degrees Pharmaceuticals | $0.9563 | −5.32% | −42.4% | −32.5% | −1152.6% | — | $3.4M | Compare |
| KALAKALA BIO | $0.1781 | +2.95% | −96.9% | — | — | — | $3.4M | Compare |
| APVOAptevo Therapeutics | $1.37 | +0.74% | −72.3% | — | — | — | $2.5M | Compare |
| HCWBHCW Biologics | $1.08 | −6.09% | −48.6% | +1969.7% | −11340.3% | — | $2.4M | Compare |
| MDCXMedicus Pharma | $1.88 | −7.39% | −88.7% | — | — | — | $3.6M | Compare |
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
